The study found that the price tag for the second-generation Bruton tyrosine kinase inhibitor would need to be reduced by 30% ...
This month’s Enterprise Connect AI show provided attendees with a look at vertical use cases, end user adoptions – and lessons on how to deploy AI in your own enterprise.
Truist Financial analyst Nicole Germino assigned a Buy rating to the stock today. The company’s shares closed yesterday at $13.00.
Detailed price information for Vivos Therapeutics Inc (VVOS-Q) from The Globe and Mail including charting and trades.
We reached out to VCs to nominate prominent founders in the industry who are committed to bringing potentially life-changing ...
Discover visionary biotech entrepreneurs, nominated by VCs, who are revolutionizing the industry with innovative, ...
Intellia Therapeutics' innovative gene editing technology could revolutionize medicine, but investors need a strong stomach ...
SAVANNAH, Georgia — There’s no medical treatment for Charcot-Marie-Tooth (CMT) disease, a debilitating neurologic disorder ...
A former The X Factor contestant who competed on the same series as Liam Payne has shared her reaction to the One Direction ...
According to The Insight Partners study on the Radiation Oncology Market is observing significant growth owing to the ...
Lessons learned from his bid to earn playing time at JUCO and a bounce back from a serious knee injury buoy Delaware's recent starter Zach Marker.